May peripheral blood hemoglobin concentration be a prognostic factor among patients diagnosed with metastatic clear cell renal carcinoma treated with targeted therapies?

Authors

  • Tomasz Ciszewski Department of Chemotherapy, St John’s Cancer Center, Lublin, Poland Author
  • Tomasz Kubiatowski Department of Chemotherapy, St John’s Cancer Center, Lublin, Poland Author
  • Justyna Szumiło Department of Clinical Pathomorphology, Medical University in Lublin, Lublin, Poland Author https://orcid.org/0000-0003-2315-4208
  • Elżbieta Starosławska Department of Chemotherapy, St John’s Cancer Center, Lublin, Poland Author
  • Krzysztof J. Czarnocki St John’s Cancer Center, Lublin, Poland, Occupational Hygiene and Ergonomic Dept., Lublin University of Technology, Lublin, Poland Author https://orcid.org/0000-0001-8790-9417
  • Franciszek Burdan St John’s Cancer Center, Lublin, Poland, Department of Human Anatomy, Medical University in Lublin, Lublin, Poland Author https://orcid.org/0000-0001-5305-8829

DOI:

https://doi.org/10.12923/

Keywords:

metastatic clear cell renal carcinoma, targeted therapies, anemia, prognostic factors

Abstract

Molecular targeted agents that are registered for the treatment of metastatic clear cell renal carcinoma significantly improved prognosis of patients with such diagnosis. Because the treatment costs are high, the problem of predicting the response to applied therapy and objective estimation of patient prognosis seems to be very important at present. The aim of the current study was the evaluation of peripheral blood hemoglobin concentration – parameter measured on different stages of treatment, as a prognostic factor. The analysis that was performed revealed that hemoglobin level may be useful in determining prognosis among patients diagnosed with metastatic clear cell renal carcinoma. Measurements performed before beginning of targeted therapy as well as after its termination seem to have prognostic value.

References

1. Bamias A. et al: Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model. BMC Cancer, 10, 45, 2010

2. Bono P. et al: Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma. Acta Oncol., 50, 569, 2011

3. Escudier B. et al: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet, 370, 2103, 2007

4. Fernández Gómez J.M. et al: Significance of anemia as an independent prognostic factor in patients with renal cell carcinoma. Med. Clin. (Barc.), 133, 407, 2009

5. Fisher R.I., Rosenberg S.A., Fyfe G.: Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J. Sci. Am., 6 Suppl. 1, 55, 2000

6. Heng D. et al: Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study. J. Clin. Oncol., 27, 5794, 2009

7. Hudes G. et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med., 356, 2271, 2007

8. Medical Research Council Renal Cancer Collaborators: Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet, 353, 14, 1999

9. Motzer R., Bander N.H., Nanus D.M.: Renal-cell carcinoma. N. Engl. J. Med., 335, 865, 1996

10. Motzer R. et al: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol., 17, 2530, 1999

11. Motzer R. et al: Interferon- alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol., 20, 289, 2002

12. Motzer R. et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med., 356, 115, 2007

13. Motzer R. et al: Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma. Cancer, 116, 4256, 2010

14. Patil S. et al: Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann. Oncol., 22, 295, 2011

15. Riesenbeck L.M. et al: Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. World J. Urol., 29, 807, 2011

16. Rini B.I. et al: Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int., 98,756, 2006

17. Sunela K.L., Kataja M.J., Kellokumpu-Lehtinen P.L.: Changes in symptoms of renal cell carcinoma over four decades. BJU Int., 106, 649, 2010

18. Therasse P. et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst., 92, 205, 2000

19. Yates J.W., Chalmer B., McKegney F.P.: Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer, 45, 2220, 1980

Annales Sectio DDD, XXIV, 4

Downloads

Published

2012-10-24

Issue

Vol. 24 No. 4 (2011): Annales UMCS, Pharmacia, Sectio DDD, Volume XXIV

Section

Artykuły

License

Copyright (c) 2011 Authors

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.

How to Cite

Ciszewski, T., Kubiatowski, T., Szumiło, J., Starosławska, E., Czarnocki, K. J., & Burdan, F. (2012). May peripheral blood hemoglobin concentration be a prognostic factor among patients diagnosed with metastatic clear cell renal carcinoma treated with targeted therapies?. Current Issues in Pharmacy and Medical Sciences, 24(4), 105-114. https://doi.org/10.12923/